How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. RARE Act (H.R.7383) - All provisions
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2024 · fourth_quarter · Q4
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Source: Senate LDA
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Further Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Further Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Further Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Further Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Department of Defense Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Department of Defense Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Consolidated Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Protecting Health Care for All Patients Act of 2023
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Protecting Health Care for All Patients Act of 2023
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Protecting Health Care for All Patients Act of 2023
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Protecting Health Care for All Patients Act of 2023
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. RARE Act (H.R.7383) - All provisions
Telehealth Modernization Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Telehealth Modernization Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Continuing Appropriations and Extensions Act, 2025
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Continuing Appropriations and Extensions Act, 2025
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. RARE Act (H.R.7383) - All provisions
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Connecting Caregivers to Medicare Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Improving Seniors’ Timely Access to Care Act of 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. RARE Act (H.R.7383) - All provisions
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. (No bill number) - Discussion Surrounding improving the prior authorization process in Medicare, Medicare Advantage, and private / individual insurance marketplaces.
Justice for ALS Veterans Act of 2023
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Justice for ALS Veterans Act (H.R 3790 / S. 1590) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. (No bill number) - Discussion Surrounding improving the prior authorization process in Medicare, Medicare Advantage, and private / individual insurance marketplaces.
Department of Defense Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Department of Defense Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Client: THE ALS ASSOCIATION · Firm: THE ALS ASSOCIATION
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases. Seniors Timely Access to Care (S.4532 / H.R. 8702) - All provisions
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. RARE Act (H.R.7383) - All provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2024 · third_quarter · Q3
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance. Seniors Timely Access to Care (S.4532 / H.R. 8702) - CONNECT for Health Act of 2023 (H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Telehealth Modernization Act (H.R. 7623 / S. 3967) - All Provisions. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. Connecting Caregivers to Medicare Act of 2024 (H.R. 7274/S. 3766) - All provisions. Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 1691) - All provisions HEALTHY BRAINS Act (H.R. 9233) - All Provisions relating to creating a research grant program to study environmental toxin exposure, its impact on the development of neurodegenerative diseases like ALS, and developing strategies to prevent, treat, and slow the progression of neurodegenerative diseases.
Further Consolidated Appropriations Act of 2024 (HR 2882) & Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. Consolidated Appropriations Act of 2024 (HR 4366) . Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Continuing Appropriations and Extensions Act, 2025 (H.R.9747) - Provisions related to continuing resolution funding for public health programs, veterans administration, and the Food and Drug Administration. Conversations surrounding Appropriations for Fiscal Year 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2024 · second_quarter · Q2
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act - All provisions
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2024 · first_quarter · Q1
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
HR 2882, Further Consolidated Appropriations Act of 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. HR 4366, the Consolidated Appropriations Act of 2024. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Conversations surrounding Appropriations for Fiscal Year 2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2025 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for Health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. H.R. 7274/S. 3766 - Connecting Caregivers to Medicare Act of 2024 - All provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2023 · fourth_quarter · Q4
Promising Pathways Act (H.R. 4408/S. 1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS and coverage for these drugs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Discussion around improving the prior authorization process for treatments and drugs under Medicare, Medicare Advantage, and private insurance. CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2023 · third_quarter · Q3
Conversations surrounding Appropriations for Fiscal Year 2024 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (S. 2624) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 4368) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. - Department of Defense Appropriations Act (H.R. 4365) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2023 · second_quarter · Q2
Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Conversations surrounding Appropriations for Fiscal Year 2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (no bill number) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue CDCs National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (no bill number) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (no bill number) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2023 · first_quarter · Q1
Justice for ALS Veterans Act (draft legislation. no bill number) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
Conversations surrounding Appropriations for Fiscal Year 2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations (no bill number) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $150 million for ALS research at NIH in fiscal year 2024 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $15 million to continue the National ALS Registry and Biorepository in fiscal year 2024 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and biospecimens, and support research of ALS prevention in the military. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (no bill number) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2024 to fund P.L. 117-79 the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide ALS research grants. Department of Defense Appropriations Act (no bill number) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $80 million for the ALS Research Program in fiscal year 2024 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2022 · fourth_quarter · Q4
-Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); provisions related to extending marketplace subsidies under the Patient Protection and Affordable Care Act; and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. Advancing Telehealth Beyond COVID-19 Act of 2021 (H.R. 4040) -- Provisions related to extension of Medicare flexibilities including originating site, allowance of occupational and physical therapists, speech-language pathologists, and audiologists to continue to provide services, allowance for qualified health centers and rural health clinics to serve as a distant site, behavioral services to continue to be provided via audio-only technology, and allowance of hospice physicians and nurse practitioners to complete patient recertification via telehealth. Additional provisions related to delay of in-person evaluation requirements for mental health services until January 1, 2025 or end of emergency period. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (H.R. 2903 / S. 1512) Provisions related to the Centers for Medicare & Medicaid Services (CMS) to waive certain restrictions, such as geographic restrictions, for services provided in high-need health professional shortage areas; excludes mental health and emergency medical services, as well as services provided at rural health clinics, federally qualified health centers, and Indian Health Service facilities, from such geographic restrictions; and waive coverage restrictions during national emergencies. -Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708 / S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e. coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory may investigate and take disciplinary actions against a processional who provides services pursuant to this bill to a patient in that body's jurisdiction. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. -Medicare Payment Reform for People with ALS (H.R.9638) Provides supplemental payment to designated ALS clinics that provide multidisciplinary services to people living with ALS. -Seniors Timely Access to Care Act (H.R.3173 / S.3018) -- Requires streamlined prior authorization process under Medicare Advantage Plans.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2022 · third_quarter · Q3
-Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (H.R.8295) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $135 million for ALS research at NIH in fiscal year 2023 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2023 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. Requested funding to establish the Advanced Research Projects Agency for Health to fund new research into Amyotrophic Lateral Sclerosis. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023 (H.R.8239) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2023 to to implement P.L. 117-79 to establish the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide grants for clinical trials for ALS and other neurodegenerative diseases.- - Department of Defense Appropriations Act, 2023 (H.R.8236) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2023 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2022 · second_quarter · Q2
-The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (H.R. 2903/ S. 1512) expands coverage of telehealth services under Medicare. Among other things, the bill allows the Centers for Medicare & Medicaid Services (CMS) to waive certain restrictions, such as geographic restrictions, for services provided in high-need health professional shortage areas; excludes mental health and emergency medical services, as well as services provided at rural health clinics, federally qualified health centers, and Indian Health Service facilities, from such geographic restrictions; and allows the CMS to generally waive coverage restrictions during national emergencies. Additionally, the Medicare Payment Advisory Commission must report on information relating to the access of Medicare beneficiaries to telehealth services at home. The Center for Medicare and Medicaid Innovation may also test alternative payment models relating to expanded telehealth services. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. -Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. -Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R.708/S.168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e. coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individuals authorization to practice in any on e state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory may investigate and take disciplinary actions against a processional who provides services pursuant to this bill to a patient in that body's jurisdiction.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2022 · first_quarter · Q1
- CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Conversations surrounding Prescription Drug User Fee Act VII (PDUFA VII) -- provisions related to modernization of regulatory evidence generation and drug development tools through novel clinical trial design and modeling, improving accountability and transparency of the FDA, enhancing staff retention and resource management.
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $135 million for ALS research at NIH in fiscal year 2023 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations LHHS Subcommittee provide at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2023 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2023 to to implement P.L. 117-79 to establish the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide grants for clinical trials for ALS and other neurodegenerative diseases. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2023 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2021 · fourth_quarter · Q4
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H). Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare bill, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2021 · third_quarter · Q3
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $130 million for ALS research at NIH in fiscal year 2022 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2022 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $50 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2022 to increase the number of ALS clinical trials and allow FDA to apply their own unique regulatory expertise in those trials to expedite treatment development, foster innovative trial designs that complement and speed regulatory processes, and enable natural history studies to more quickly understand ALS progression and pathology. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2022 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $1 million for a National Academies of Science, Engineering and Medicine study to develop a plan and policy recommendations for what can be done by the government and all stakeholders to end ALS.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2021 · second_quarter · 2A
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $130 million for ALS research at NIH in fiscal year 2022 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2022 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $50 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2022 to increase the number of ALS clinical trials and allow FDA to apply their own unique regulatory expertise in those trials to expedite treatment development, foster innovative trial designs that complement and speed regulatory processes, and enable natural history studies to more quickly understand ALS progression and pathology. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2022 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $1 million for a National Academies of Science, Engineering and Medicine study to develop a plan and policy recommendations for what can be done by the government and all stakeholders to end ALS.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2021 · second_quarter · Q2
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $130 million for ALS research at NIH in fiscal year 2022 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2022 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $50 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2022 to increase the number of ALS clinical trials and allow FDA to apply their own unique regulatory expertise in those trials to expedite treatment development, foster innovative trial designs that complement and speed regulatory processes, and enable natural history studies to more quickly understand ALS progression and pathology. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2022 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $1 million for a National Academies of Science, Engineering and Medicine study to develop a plan and policy recommendations for what can be done by the government and all stakeholders to end ALS.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2021 · first_quarter · Q1
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $130 million for ALS research at NIH in fiscal year 2022 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2022 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $50 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2022 to increase the number of ALS clinical trials and allow FDA to apply their own unique regulatory expertise in those trials to expedite treatment development, foster innovative trial designs that complement and speed regulatory processes, and enable natural history studies to more quickly understand ALS progression and pathology. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2022 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $1 million for a National Academies of Science, Engineering and Medicine study to develop a plan and policy recommendations for what can be done by the government and all stakeholders to end ALS.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2020 · fourth_quarter · Q4
Requested that House and Senate Defense Appropriations Subcommittee provide $40 million for the ALS Research Program at the Department of Defense, a $20 million increase over the ALSRP's funding in FY2020. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $44.7 billion for the NIH, a $3 billion increase over NIHs program level funding in FY 2020. This funding level would allow for meaningful growth above inflation in the base budget and would expand NIHs capacity to support promising science in all disciplines across the agency. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2020 · third_quarter · Q3
Requested that House and Senate Defense Appropriations Subcommittee provide $40 million for the ALS Research Program at the Department of Defense, a $20 million increase over the ALSRP's funding in FY2020. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $44.7 billion for the NIH, a $3 billion increase over NIHs program level funding in FY 2020. This funding level would allow for meaningful growth above inflation in the base budget and would expand NIHs capacity to support promising science in all disciplines across the agency. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2020 · second_quarter · Q2
Requested that House and Senate Defense Appropriations Subcommittee provide $40 million for the ALS Research Program at the Department of Defense, a $20 million increase over the ALSRP's funding in FY2020. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $44.7 billion for the NIH, a $3 billion increase over NIHs program level funding in FY 2020. This funding level would allow for meaningful growth above inflation in the base budget and would expand NIHs capacity to support promising science in all disciplines across the agency. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2020 · first_quarter · Q1
Requested that House and Senate Defense Appropriations Subcommittee provide $40 million for the ALS Research Program at the Department of Defense, a $20 million increase over the ALSRP's funding in FY2020. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $44.7 billion for the NIH, a $3 billion increase over NIHs program level funding in FY 2020. This funding level would allow for meaningful growth above inflation in the base budget and would expand NIHs capacity to support promising science in all disciplines across the agency. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2019 · fourth_quarter · Q4
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance.
Requested that House and Senate Defense Appropriations Subcommittee provide $20 million for the ALS Research Program at the Department of Defense, a $10 million increase over the ALSRP's funding in FY2019. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $41.6 billion in FY2020 for the National Institutes of Health (NIH), a $2.5 billion increase over the NIHs program level funding in FY 2019. This funding level would allow for meaningful growth above inflation in the base budget that would expand NIHs capacity to support promising science in all disciplines. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2019 · third_quarter · Q3
Requested that House and Senate Defense Appropriations Subcommittee provide $20 million for the ALS Research Program at the Department of Defense, a $10 million increase over the ALSRP's funding in FY2019. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $41.6 billion in FY2020 for the National Institutes of Health (NIH), a $2.5 billion increase over the NIHs program level funding in FY 2019. This funding level would allow for meaningful growth above inflation in the base budget that would expand NIHs capacity to support promising science in all disciplines. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2019 · second_quarter · Q2
Requested that House and Senate Defense Appropriations Subcommittee provide $20 million for the ALS Research Program at the Department of Defense, a $10 million increase over the ALSRP's funding in FY2019. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $41.6 billion in FY2020 for the National Institutes of Health (NIH), a $2.5 billion increase over the NIHs program level funding in FY 2019. This funding level would allow for meaningful growth above inflation in the base budget that would expand NIHs capacity to support promising science in all disciplines. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2019 · first_quarter · Q1
Reintroduced ALS Disability Insurance Access Act (S.578/H.R.1407) for the 116th Congress to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance. Supported legislation (H.R.1010) to provide that the rule entitled "Short Term, Limited Duration Insurance" shall have no force or effect. Originally intended as temporary bridge or gap plans, short-term limited-duration health insurance policies have lower premiums than other plans on the market because they are exempt from many of the key requirements (including protections for pre-existing conditions and do not have to provide ACA-compliant Essential Health Benefits) that provide comprehensive coverage and protect consumers from high out-of-pocket costs.
Requested that House and Senate Defense Appropriations Subcommittee provide $20 million for the ALS Research Program at the Department of Defense, a $10 million increase over the ALSRP's funding in FY2019. This funding level would enable the ALSRP to refocus efforts on making investments in early phase clinical trials (Phase 1-2) to de-risk early phase trials for ALS, bridging the valley of death to make private investment into ALS more possible. With a number of promising ALSRP-funded preclinical projects with the potential to enter early phase trials, now is the time to increase investment in this critical gap in the ALS research continuum. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $10 million in FY2020, level funding over the programs FY2019 funding, for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Requested that House and Senate Labor-Health-Human Services (LHHS) Appropriations Subcommittee provide $41.6 billion in FY2020 for the National Institutes of Health (NIH), a $2.5 billion increase over the NIHs program level funding in FY 2019. This funding level would allow for meaningful growth above inflation in the base budget that would expand NIHs capacity to support promising science in all disciplines. It also would ensure that funding from the Innovation Account established in the 21st Century Cures Act would supplement the agencys base budget, as intended, through dedicated funding for specific programs.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2018 · fourth_quarter · Q4
Defense Appropriations for FY2019 to provide $20 million for the ALS Research Program at the Department of Defense.
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance. Ensuring Coverage for Patients with Pre-Existing Conditions Act (S.3388) to oppose the legislation and go further in supporting protections for insurance coverage for people with pre-existing conditions.
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2018 · third_quarter · Q3
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
Labor-Health-Human Services (LHHS) Appropriations for FY2019 to provide $10 million for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Labor-Health-Human Services (LHHS)Appropriations for FY2019 to provide $39.3 billion for the National Institutes of Health. Defense Appropriations for FY2019 to provide $10 million for the ALS Research Program at the Department of Defense.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2018 · second_quarter · Q2
Labor-Health-Human Services (LHHS) Appropriations for FY2019 to provide $10 million for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Labor-Health-Human Services (LHHS)Appropriations for FY2019 to provide $39.3 billion for the National Institutes of Health. Defense Appropriations for FY2019 to provide $10 million for the ALS Research Program at the Department of Defense.
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2018 · first_quarter · Q1
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
Tax Cuts and Jobs Act (H.R.1) to maintain the Medical Expense Tax Deduction and allow a deduction with an income threshold for qualifying expenses at 7.5 percent. Tax Cuts and Jobs Act (H.R.1) to maintain the Orphan Drug Tax Credit (ODTC) to lower the cost of developing and testing orphan therapies for biopharmaceutical companies who develop drugs for diseases like ALS that affect fewer than 200,00 people at one time.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2017 · fourth_quarter · Q4
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
Tax Cuts and Jobs Act (H.R.1) to maintain the Medical Expense Tax Deduction and allow a deduction with an income threshold for qualifying expenses at 7.5 percent. Tax Cuts and Jobs Act (H.R.1) to maintain the Orphan Drug Tax Credit (ODTC) to lower the cost of developing and testing orphan therapies for biopharmaceutical companies who develop drugs for diseases like ALS that affect fewer than 200,00 people at one time.
THE ALS ASSOCIATION via THE ALS ASSOCIATION
2017 · fourth_quarter · RR
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data.
CONNECT for health Act of 2023(H.R.4189/S.2016) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs. BENEFIT Act of 2023 (H.R.1092/S.526) - Provisions related to increases in patient and advocate role in FDA benefit-risk framework for drug approval through leveraging patient experience, PFDD, and related data. (No bill number) - Discussion Surrounding improving the prior authorization process in Medicare, Medicare Advantage, and private / individual insurance marketplaces.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(No bill number) - Discussion Surrounding improving the prior authorization process in Medicare, Medicare Advantage, and private / individual insurance marketplaces. Discussion around Telehealth permanence (no bill number) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542 / S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830 / S.1375) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs.
Justice for ALS Veterans Act (H.R 3790 / S. 1590) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
ALS Better Care Act (Draft Legislation. no bill number) - Provides supplemental payment to designated ALS clinics that provide multidisciplinary services to people living with ALS. Discussion around Telehealth permanence (no bill number) - provisions related to permanent telehealth services in Medicare and interstate telehealth services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALS Better Care Act (Draft Legislation. no bill number) - Provides supplemental payment to designated ALS clinics that provide multidisciplinary services to people living with ALS. Discussion around Telehealth permanence (no bill number) - provisions related to permanent telehealth services in Medicare and interstate telehealth services.
Promising Pathways Act (draft legislation. no bill number) - would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Discussion around Telehealth permanence (no bill number) - provisions related to permanent telehealth services in Medicare and interstate telehealth services. Protecting Health Care for All Patients Act of 2023 (H.R. 485) - provisions to ban the usage of quality adjusted life years in public insurance programs. Elizabeth Dole Home Care Act of 2023 (H.R. 542/S.141) - would raise the cap on the Veterans Administrations payments for home care from 65% to 100% and would expand VA home care programs. HELP Copays Act (H.R.830) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave.
Justice for ALS Veterans Act (H.R. 5607 / S.3483) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
-Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (H.R.8295) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $135 million for ALS research at NIH in fiscal year 2023 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2023 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. Requested funding to establish the Advanced Research Projects Agency for Health to fund new research into Amyotrophic Lateral Sclerosis. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023 (H.R.8239) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2023 to to implement P.L. 117-79 to establish the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide grants for clinical trials for ALS and other neurodegenerative diseases.- - Department of Defense Appropriations Act, 2023 (H.R.8236) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2023 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. - Consolidated Appropriations Act (H.R.2617) -- supported provisions in legislation related to ALS research funding directed towards NIH, FDA, CDC, and DOD.
- CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. -Food and Drug Amendments of 2022 (H.R. 7667) / PDUFA VII-- provisions related to accelerated approval program, clinical trial diversity, novel clinical trial design and modeling, improving accountability and transparency of the FDA.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); provisions related to extending marketplace subsidies under the Patient Protection and Affordable Care Act; and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. - Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19. - HELP Copays Act (H.R.5801) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Justice for ALS Veterans Act (H.R. 5607 / S.3483) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
-Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); provisions related to extending marketplace subsidies under the Patient Protection and Affordable Care Act; and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. Advancing Telehealth Beyond COVID-19 Act of 2021 (H.R. 4040) -- Provisions related to extension of Medicare flexibilities including originating site, allowance of occupational and physical therapists, speech-language pathologists, and audiologists to continue to provide services, allowance for qualified health centers and rural health clinics to serve as a distant site, behavioral services to continue to be provided via audio-only technology, and allowance of hospice physicians and nurse practitioners to complete patient recertification via telehealth. Additional provisions related to delay of in-person evaluation requirements for mental health services until January 1, 2025 or end of emergency period. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (H.R. 2903 / S. 1512) Provisions related to the Centers for Medicare & Medicaid Services (CMS) to waive certain restrictions, such as geographic restrictions, for services provided in high-need health professional shortage areas; excludes mental health and emergency medical services, as well as services provided at rural health clinics, federally qualified health centers, and Indian Health Service facilities, from such geographic restrictions; and waive coverage restrictions during national emergencies. -Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708 / S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e. coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory may investigate and take disciplinary actions against a processional who provides services pursuant to this bill to a patient in that body's jurisdiction. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); provisions related to extending marketplace subsidies under the Patient Protection and Affordable Care Act; and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. - Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19. - HELP Copays Act (H.R.5801) -- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs.
- CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. -Food and Drug Amendments of 2022 (H.R. 7667) / PDUFA VII-- provisions related to accelerated approval program, clinical trial diversity, novel clinical trial design and modeling, improving accountability and transparency of the FDA.
Inflation Reduction Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Justice for ALS Veterans Act (H.R. 5607 / S.3483) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave.
- CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. -Food and Drug Amendments of 2022 (H.R. 7667) / PDUFA VII-- provisions related to accelerated approval program, clinical trial diversity, novel clinical trial design and modeling, improving accountability and transparency of the FDA.
-Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. -CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; the establishment Advanced Research Projects Agency for Health (ARPA-H); and provisions related to an out-of-pocket maximum for Medicare beneficiaries' prescription drugs. - Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare bill, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19. - HELP Copays Act (H.R.5801)-- Provisions related to health insurance plans requirement to apply payments made by or on behalf of plan enrollees toward a plan's cost-sharing requirements, i.e. a ban on copay-accumulator adjust programs.
-Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 (H.R.8295) --Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $135 million for ALS research at NIH in fiscal year 2023 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. Requested at least $75 000,000 to implement the expanded access program established by the ACT for ALS Act (P.L. 117-79). Requested at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2023 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. Requested funding to establish the Advanced Research Projects Agency for Health to fund new research into Amyotrophic Lateral Sclerosis. - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023 (H.R.8239) --Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $25 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2023 to to implement P.L. 117-79 to establish the FDA Rare Neurodegenerative Disease Grant Program which is authorized to provide grants for clinical trials for ALS and other neurodegenerative diseases.- - Department of Defense Appropriations Act, 2023 (H.R.8236) -- Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2023 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS. CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. - Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H). - Telehealth Modernization Act (H.R. 1332/S. 368) -- Provisions related to the modification of requirements relating to coverage of telehealth services under Medicare bill, including certain flexibilities that were initially authorized during the public health emergency relating to COVID-19. - ACT for ALS (P.L. 117-70) - Conversations surrounding implementation of PL 117-79, the Accessing Critical Therapies for ALS Act.
Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave.
-The Telehealth Modernization Act (H.R. 1332/ S. 368) extends certain COVID telehealth flexibilities. Among other things, the bill allows (1) rural health clinics and federally qualified health centers to serve as the distant site (i.e., the location of the health care practitioner); (2) the home of a beneficiary to serve as the originating site (i.e., the location of the beneficiary) for all services (rather than for only certain services); and (3) all types of practitioners to furnish telehealth services, as determined by the Centers for Medicare & Medicaid Services. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (H.R. 2903/ S. 1512) expands coverage of telehealth services under Medicare. Among other things, the bill allows the Centers for Medicare & Medicaid Services (CMS) to waive certain restrictions, such as geographic restrictions, for services provided in high-need health professional shortage areas; excludes mental health and emergency medical services, as well as services provided at rural health clinics, federally qualified health centers, and Indian Health Service facilities, from such geographic restrictions; and allows the CMS to generally waive coverage restrictions during national emergencies. Additionally, the Medicare Payment Advisory Commission must report on information relating to the access of Medicare beneficiaries to telehealth services at home. The Center for Medicare and Medicaid Innovation may also test alternative payment models relating to expanded telehealth services. CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H).
Justice for ALS Veterans Act (H.R. 5607 / S.3483) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Justice for ALS Veterans Act (H.R. 5607 / S.3483) -- All Provisions, including those extending Dependency and Indemnity Compensation payments to surviving spouses of veterans who die from ALS, regardless of how long a veteran had ALS prior to death.
Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave.
-Requested that the House and Senate Appropriations LHHS Subcommittee provide at least $130 million for ALS research at NIH in fiscal year 2022 to attract the next generation of scientists, accelerate the discovery and development of new treatments and increase the number of ALS clinical trials. -Requested the House and Senate Appropriations Defense Subcommittee provide at least $60 million for the ALS Research Program in fiscal year 2022 to allow the program to build on a solid foundation of promising preclinical research to increase the number of ALS clinical trials by funding its own early phase trials. -Requested the House and Senate Appropriations Agriculture Subcommittee provide at least $50 million specifically for ALS research to the FDA Orphan Products Grants Program in fiscal year 2022 to increase the number of ALS clinical trials and allow FDA to apply their own unique regulatory expertise in those trials to expedite treatment development, foster innovative trial designs that complement and speed regulatory processes, and enable natural history studies to more quickly understand ALS progression and pathology. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $10 million to continue the National ALS Registry and Biorepository in fiscal year 2022 to help identify risk factors for ALS to reduce the number of new cases, connect patients with clinical trials, conduct surveillance of incidence and prevalence and collect biospecimens that will lead to a better understanding of who may develop ALS. -Requested House and Senate Appropriations LHHS Subcommittee provide at least $1 million for a National Academies of Science, Engineering and Medicine study to develop a plan and policy recommendations for what can be done by the government and all stakeholders to end ALS.
-The Telehealth Modernization Act (H.R. 1332/ S. 368) extends certain COVID telehealth flexibilities. Among other things, the bill allows (1) rural health clinics and federally qualified health centers to serve as the distant site (i.e., the location of the health care practitioner); (2) the home of a beneficiary to serve as the originating site (i.e., the location of the beneficiary) for all services (rather than for only certain services); and (3) all types of practitioners to furnish telehealth services, as determined by the Centers for Medicare & Medicaid Services. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (H.R. 2903/ S. 1512) expands coverage of telehealth services under Medicare. Among other things, the bill allows the Centers for Medicare & Medicaid Services (CMS) to waive certain restrictions, such as geographic restrictions, for services provided in high-need health professional shortage areas; excludes mental health and emergency medical services, as well as services provided at rural health clinics, federally qualified health centers, and Indian Health Service facilities, from such geographic restrictions; and allows the CMS to generally waive coverage restrictions during national emergencies. Additionally, the Medicare Payment Advisory Commission must report on information relating to the access of Medicare beneficiaries to telehealth services at home. The Center for Medicare and Medicaid Innovation may also test alternative payment models relating to expanded telehealth services. CURES 2.0 Act (H.R. 6000) -- Provisions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms. Build Back Better Act (H.R. 5376) -- Provisions related to providing up to 12 weeks of paid family and medical leave; extending Medicare telehealth flexibilities beyond the COVID-19 public health emergency; and the establishment Advanced Research Projects Agency for Health (ARPA-H).
CURES 2.0 Act (H.R. 6000) -- Previsions related to drug development, research, and access to emerging therapies for Americans with ALS and other rare diseases through the creation of ARPA-H and other mechanisms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/ S. 168) temporarily authorizes the interstate provision of in-person and telehealth services. This authorization applies during, and for at least 180 days after, the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, subject to scope of practice and other requirements, a health care professional may provide health services in any U.S. jurisdiction based on that individual's authorization to practice in any one state or territory. The bill also provides certain related powers to health care professional regulatory bodies, such as medical boards. Specifically, a regulatory body may investigate and take disciplinary actions against a professional who provides services pursuant to this bill to a patient in that body's jurisdiction. -The Promising Pathway Act (S. 1644) would establish a new time-limited "provisional approval" path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. -Accelerating Access to Critical Therapies (ACT) for ALS Act (H.R. 3537/ S. 1813) would create 1) a new framework for delivering experimental therapies to people with rare neurodegenerative diseases such as ALS; 2) create a new research grant program at the FDA to such diseases, and; 3) create a new Public-Private Partnership at the Department of Health and Human Services to coordinate federal efforts on developing and approving treatments for such diseases. -Promising Pathway Act (H.R. 3761/S. 1644) would create a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance. The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) would expand access to telemedicine and telehealth for people with ALS through a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method. Additionally, all changes made to expand access to telehealth during the COVID-19 public health emergency should be permanently extended. Promising Pathway Act (H.R. 7269/ S. 3872) to establish a new time-limited provisional approval path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. Accelerating Critical Therapies for ALS Act (H.R. 7071) reintroduced as H.R. 8662/ S. 4867 to create 1) a new framework for delivering experimental therapies to people with ALS; 2) a new research grant program at the FDA for rare neurodegenerative diseases, and; 3) a new Collaborative for Rare Neurodegenerative Diseases at the Department of Health and Human Services (HHS) to coordinate federal efforts on developing and approving effective treatments and cures.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance. The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) would expand access to telemedicine and telehealth for people with ALS through a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method. Additionally, all changes made to expand access to telehealth during the COVID-19 public health emergency should be permanently extended. Promising Pathway Act (H.R. 7269/ S. 3872) to establish a new time-limited provisional approval path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. Accelerating Critical Therapies for ALS Act (H.R. 7071) reintroduced as H.R. 8662/ S. 4867 to create 1) a new framework for delivering experimental therapies to people with ALS; 2) a new research grant program at the FDA for rare neurodegenerative diseases, and; 3) a new Collaborative for Rare Neurodegenerative Diseases at the Department of Health and Human Services (HHS) to coordinate federal efforts on developing and approving effective treatments and cures.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance. The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) would expand access to telemedicine and telehealth for people with ALS through a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method. Additionally, all changes made to expand access to telehealth during the COVID-19 public health emergency should be permanently extended. Promising Pathway Act (H.R. 7269/ S. 3872) to establish a new time-limited provisional approval path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. Accelerating Critical Therapies for ALS Act (H.R. 7071) to establish a grant program to provide access to experimental drugs to people with ALS and other rapidly progressing neurological diseases for which effective therapies do not currently exist and create a Center of Excellence for Neurodegenerative Diseases at the FDA to speed the development and approval of therapies for neurodegenerative diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance. Ensuring Coverage for Patients with Pre-Existing Conditions Act (S.3388) to oppose the legislation and go further in supporting protections for insurance coverage for people with pre-existing conditions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance.
Submitted comments to FDA regarding Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment; Draft Guidance for Industry (Docket No. FDA-2013-N-0035) and hosted a public forum that provided the FDA with targeted feedback and information from people with ALS, caregivers, and stakeholders to ensure the patient voice in the FDAs Draft Guidance on ALS Drug Development.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Labor-Health-Human Services (LHHS) Appropriations for FY2018 and FY2019 to provide $10 million for the National ALS Registry and Biorepository at the Centers for Disease Control and Prevention. Labor-Health-Human Services (LHHS)Appropriations for FY2018 and FY2019 to provide $39.3 billion for the National Institutes of Health. Defense Appropriations for FY2018 and FY2019 to provide $10 million for the ALS Research Program at the Department of Defense.
ALS Disability Insurance Access Act (S.379/H.R.1171) to waive the five-month waiting period for patients with ALS before receiving benefits under Social Security Disability Insurance. Steve Gleason Enduring Voices Act (S.1132 and H.R.2465) to permanently fix the current Centers for Medicare and Medicaid Services (CMS) policy limiting access to Speech Generating Devices (SGD) for people with degenerative diseases like ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS
Appropriations (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Budget (DOD and LHHS) - DOD ALS Research Program, CDC National ALS Registry, NIH Drug development Health Care Reform - Reforms affecting people with ALS Medicare/ Medicaid - Home Health Prospective Payment System Social Security - Waive SSDI waiting period for people with ALS